NanoViricides (NYSE-A:NNVC) is preparing a Phase II clinical trial application for its lead antiviral candidate NV-387 to treat Mpox infections in Central Africa, marking a major step in the company’s broader strategy to address a growing range of viral public health threats with no currently approved treatments.
The Connecticut-based biotech firm recently received clearance from the Democratic Republic of Congo’s National Ethics Committee to proceed with the submission following a review of Phase I safety data and promising results from preclinical Mpox studies in lethal animal models.
StickIt Technologies Inc. (CSE:STKT) announced that it has strengthened its leadership team with the appointment of Igor Kostioutchenko to its board of directors.
Kostioutchenko brings more than 15 years of experience in accounting and finance to the company, StickIt said in a statement on Friday.
NextSource Materials Inc. (TSX:NEXT, OTCQB:NSRCF) is advancing plans to scale up its graphite operations in Madagascar and exploring larger opportunities for downstream processing.
The Canadian miner, which operates the Molo graphite mine, said it is shifting its operational focus after completing a technical review of its Phase 1 operations.
T Stamp Inc (NASDAQ:IDAI, EURONEXT:AIID), dba Trust Stamp, announced that it expects more than $5 million in revenue from existing contracted customers for fiscal year 2025, it said in its forward-looking guidance issued alongside its first quarter filing.
The company highlighted that this estimate excludes potential revenue from contracted customers that have yet to start generating income, suggesting additional upside.
Indie game developer Everplay Group PLC (LSE:EVPL) has announced a change in leadership, with chief executive Steve Bell stepping down.
Everplay chair Frank Sagnier is taking up executive duties on an interim basis, with immediate effect, and the firm has added Penny Judd as senior independent director.